ADIPOQ and obesity disorder: In human clinical trials, dietary n-3 PUFA have been shown to increase adiponectin levels [32,33,34] in obese and overweight subjects, thereby demonstrating the potential utility of n-3 PUFA to stimulate the effects of this anti-inflammatory adipokine in obesity.